Guardant Health (GH) Stock Price Target 2026

The average analyst price target for Guardant Health is $170.07, 5.5% above the current price. Of 26 analysts, 26 rate it Buy. Targets range from $60 to $225. The latest change came on Oct 27, 2026, when BTIG raised its price target on Guardant Health from $195 to $210 and kept a Buy rating.

The Average Analyst Price Target for Guardant Health is $170.07.

Price Target Range — 8 Quarters

Analyst Consensus — 26 Analysts

26Buy

Consensus RatingBuy# Analysts26Avg. Consensus PT$170.07Upside to Avg. PT+5.5%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Guardant Health Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	BTIG	Mark Massaro	PT Raise	Buy	$195→$210
Oct 23, 2026	Roth Capital	Max Masucci	Initiate	Buy	$200
Oct 13, 2026	Morgan Stanley	Shannon O'Callaghan	PT Raise	Overweight	$185→$200
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$200→$220
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$190→$200
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Buy	$175→$225
Sep 8, 2026	Rothschild & Co	Jamie Clark	Initiate	Buy	$203
Sep 2, 2026	BTIG	Mark Massaro	Maintained	Buy	$195
Aug 4, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$135→$193
Aug 4, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$170→$195
Aug 4, 2026	Morgan Stanley	Shannon O'Callaghan	PT Raise	Overweight	$175→$185
Aug 3, 2026	Stifel	Daniel Arias	PT Raise	Buy	$130→$180
Jul 31, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$185→$200
Jul 31, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$175→$200
Jul 31, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$185→$195
Jul 31, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$200→$210
Jul 31, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$150→$200
Jul 31, 2026	BTIG	Mark Massaro	PT Raise	Buy	$190→$195
Jul 16, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$160→$190
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$135→$205

Analyst Ratings News

PRO
BTIG Maintains Buy on Guardant Health, Raises Price Target to $210

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.

Benzinga Newsdesk

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.

Avi Kapoor

PRO
Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200

Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $200.

Benzinga Newsdesk

Guardant Health Inc

Guardant Health (GH) Stock Price Target 2026

The Average Analyst Price Target for Guardant Health is $170.07.

Latest Upgrades and Downgrades for Guardant Health Stock

Analyst Ratings News

PROBTIG Maintains Buy on Guardant Health, Raises Price Target to $210

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRORoth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200

PROMorgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PROBarclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PROGuggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

PRO
BTIG Maintains Buy on Guardant Health, Raises Price Target to $210

PRO
Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

PRO
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

PRO
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200